{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:35Z","timestamp":1772119655351,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10822-024-00569-x","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:59:25Z","timestamp":1724295565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-0666","authenticated-orcid":false,"given":"Daniel A. M.","family":"Pais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Peter A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Felderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-3506","authenticated-orcid":false,"given":"Maria B.","family":"Batalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Eichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia T.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitto","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"3","key":"569_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/bab.1617","volume":"65","author":"M Kesik-Brodacka","year":"2018","unstructured":"Kesik-Brodacka M (2018) Progress in biopharmaceutical development. Biotechnol Appl Biochem 65(3):306\u2013322. https:\/\/doi.org\/10.1002\/bab.1617","journal-title":"Biotechnol Appl Biochem"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"107552","DOI":"10.1016\/j.biotechadv.2020.107552","volume":"43","author":"R O\u2019Flaherty","year":"2020","unstructured":"O\u2019Flaherty R, Bergin A, Flampouri E, Mota LM, Obaidi I, Quigley A, Xie Y, Butler M (2020) Mammalian cell culture for production of recombinant proteins: a review of the critical steps in their biomanufacturing. Biotechnol Adv 43:107552. https:\/\/doi.org\/10.1016\/j.biotechadv.2020.107552","journal-title":"Biotechnol Adv"},{"issue":"12","key":"569_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","volume":"36","author":"G Walsh","year":"2018","unstructured":"Walsh G (2018) Biopharmaceutical benchmarks 2018. Nat Biotechnol 36(12):1136\u20131145. https:\/\/doi.org\/10.1038\/nbt.4305","journal-title":"Nat Biotechnol"},{"issue":"2","key":"569_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5(2):297\u2013305. https:\/\/doi.org\/10.4161\/mabs.23684","journal-title":"MAbs"},{"issue":"12","key":"569_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421\u20131434. https:\/\/doi.org\/10.1016\/j.addr.2008.04.012","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"569_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1099-1352(200007\/08)13:4<167::AID-JMR502>3.0.CO;2-9","volume":"13","author":"A Skerra","year":"2000","unstructured":"Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13(4):167\u2013187","journal-title":"J Mol Recognit"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","volume":"60","author":"M Gebauer","year":"2020","unstructured":"Gebauer M, Skerra A (2020) Engineered protein scaffolds as next-generation therapeutics. Annu Rev Pharmacol Toxicol 60:391\u2013415. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010818-021118","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"569_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.904702","author":"MD Ganfornina","year":"2022","unstructured":"Ganfornina MD, \u00c5kerstr\u00f6m B, Sanchez D (2022) Editorial: functional profile of the lipocalin protein family. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2022.904702","journal-title":"Front Physiol"},{"issue":"5","key":"569_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/pro.5560020507","volume":"2","author":"DR Flower","year":"1993","unstructured":"Flower DR, North ACT, Attwood TK (1993) Structure and sequence relationships in the lipocalins and related proteins. Protein Sci 2(5):753\u2013761. https:\/\/doi.org\/10.1002\/pro.5560020507","journal-title":"Protein Sci"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.ircmb.2022.03.009","volume":"369","author":"A Morales-Kastresana","year":"2022","unstructured":"Morales-Kastresana A, Siegemund M, Haak S, Peper-Gabriel J, Neiens V, Rothe C (2022) Anticalin\u00ae-based therapeutics: expanding new frontiers in drug development. Int Rev Cell Mol Biol 369:89\u2013106. https:\/\/doi.org\/10.1016\/bs.ircmb.2022.03.009","journal-title":"Int Rev Cell Mol Biol"},{"issue":"19","key":"569_CR11","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","volume":"25","author":"MJ Hinner","year":"2019","unstructured":"Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, D\u00fcrr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Sch\u00fcler J, Moebius U, Rothe C, Matis L, Olwill SA (2019) Tumor-localized costimulatory T-cell engagement by the 4\u20131BB\/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res 25(19):5878\u20135889. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3654","journal-title":"Clin Cancer Res"},{"issue":"15","key":"569_CR12","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1158\/1078-0432.CCR-21-2762","volume":"28","author":"JK Peper-Gabriel","year":"2022","unstructured":"Peper-Gabriel JK, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin TJ, Gallou C, Hansbauer E-M, Richter M, Lelievre H, Scholer-Dahirel A, Bossenmaier B, Sancerne C, Riviere M, Grandclaudon M, Zettl M, Bel Aiba RS, Rothe C, Blanc V, Olwill SA (2022) The PD-L1\/4-1BB bispecific antibody-anticalin fusion protein PRS-344\/S095012 elicits strong T-cell stimulation in a tumor-localized manner. Clin Cancer Res 28(15):3387\u20133399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2762","journal-title":"Clin Cancer Res"},{"key":"569_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2023.10.003","author":"S Wachter","year":"2023","unstructured":"Wachter S, Angevin T, Bubna N, Tan A, Cichy A, Brown D, Wolfe LS, Sappington R, Lilla E, Berry L, Grismer D, Orth C, Blanusa M, Mostafa S, Kaufmann H, Felderer K (2023) Application of platform process development approaches to the manufacturing of Mabcalin\u2122 bispecifics. J Biotechnol. https:\/\/doi.org\/10.1016\/j.jbiotec.2023.10.003","journal-title":"J Biotechnol"},{"key":"569_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1743053","author":"M Bailly","year":"2020","unstructured":"Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, Yu Y, Park J, Raghava S, Welsh J, Rauscher M, Raghunathan G, Hsieh M, Chen Y-L, Nguyen HT, Fayadat-Dilman L (2020) Predicting antibody developability profiles through early stage discovery screening. MAbs. https:\/\/doi.org\/10.1080\/19420862.2020.1743053","journal-title":"MAbs"},{"key":"569_CR15","volume-title":"Developability of biotherapeutics computational approaches","author":"S Hartmann","year":"2015","unstructured":"Hartmann S, Kocher HP (2015) Chapter 7\u2014best practices in assessment of developability of biopharmaceutical candidates. In: Kumar S, Singh SK (eds) Developability of biotherapeutics computational approaches. CRC Press, Boca Raton"},{"issue":"3","key":"569_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tips.2020.12.004","volume":"42","author":"H Narayanan","year":"2021","unstructured":"Narayanan H, Dingfelder F, Butt\u00e9 A, Lorenzen N, Sokolov M, Arosio P (2021) Machine learning for biologics: opportunities for protein engineering, developability, and formulation. Trends Pharmacol Sci 42(3):151\u2013165. https:\/\/doi.org\/10.1016\/j.tips.2020.12.004","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"569_CR17","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1021\/acs.molpharmaceut.1c00469","volume":"18","author":"H Narayanan","year":"2021","unstructured":"Narayanan H, Dingfelder F, Condado Morales I, Patel B, Heding KE, Bjelke JR, Egebjerg T, Butt\u00e9 A, Sokolov M, Lorenzen N, Arosio P (2021) Design of biopharmaceutical formulation accelerated by machine learning for biologics. Mol Pharm 18(10):3843\u20133853. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00469","journal-title":"Mol Pharm"},{"issue":"2","key":"569_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/19420862.2018.1553476","volume":"11","author":"Y Xu","year":"2019","unstructured":"Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H (2019) Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 11(2):239\u2013264. https:\/\/doi.org\/10.1080\/19420862.2018.1553476","journal-title":"MAbs"},{"issue":"6","key":"569_CR19","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/jps.24430","volume":"104","author":"A Jarasch","year":"2015","unstructured":"Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104(6):1885\u20131898. https:\/\/doi.org\/10.1002\/jps.24430","journal-title":"J Pharm Sci"},{"key":"569_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.18.159798","author":"X Chen","year":"2020","unstructured":"Chen X, Dougherty T, Hong C, Schibler R, Zhao YC, Sadeghi R, Matasci N, Wu Y-C, Kerman I (2020) Predicting antibody developability from sequence using machine learning. biorxiv. https:\/\/doi.org\/10.1101\/2020.06.18.159798","journal-title":"biorxiv"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchromb.2017.09.027","volume":"1065\u20131066","author":"A Goyon","year":"2017","unstructured":"Goyon A, D\u2019Atri V, Colas O, Fekete S, Beck A, Guillarme D (2017) Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation. J Chromatogr, B: Anal Technol Biomed Life Sci 1065\u20131066:35\u201343. https:\/\/doi.org\/10.1016\/j.jchromb.2017.09.027","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"issue":"10","key":"569_CR22","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1810576116","volume":"116","author":"MIJ Raybould","year":"2019","unstructured":"Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM (2019) Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci USA 116(10):4025\u20134030. https:\/\/doi.org\/10.1073\/pnas.1810576116","journal-title":"Proc Natl Acad Sci USA"},{"key":"569_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2020082","author":"R Khetan","year":"2022","unstructured":"Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, Warwicker J, Martin ACR (2022) Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs. https:\/\/doi.org\/10.1080\/19420862.2021.2020082","journal-title":"MAbs"},{"key":"569_CR24","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8199","author":"M Hebditch","year":"2019","unstructured":"Hebditch M, Warwicker J (2019) Charge and hydrophobicity are key features in sequence-trained machine learning models for predicting the biophysical properties of clinical-stage antibodies. PeerJ. https:\/\/doi.org\/10.7717\/peerj.8199","journal-title":"PeerJ"},{"issue":"1","key":"569_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jps.22758","volume":"101","author":"TM Lauer","year":"2012","unstructured":"Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL (2012) Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101(1):102\u2013115. https:\/\/doi.org\/10.1002\/jps.22758","journal-title":"J Pharm Sci"},{"key":"569_CR26","doi-asserted-by":"publisher","first-page":"463486","DOI":"10.1016\/j.chroma.2022.463486","volume":"1682","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Bansode V, Rathore AS (2022) Application of advanced machine learning algorithms for anomaly detection and quantitative prediction in protein A chromatography. J Chromatogr A 1682:463486. https:\/\/doi.org\/10.1016\/j.chroma.2022.463486","journal-title":"J Chromatogr A"},{"issue":"5","key":"569_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41573-019-0050-3","volume":"19","author":"P Schneider","year":"2020","unstructured":"Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA, Fisher J, Jansen JM, Duca JS, Rush TS, Zentgraf M, Hill JE, Krutoholow E, Kohler M, Blaney J, Funatsu K, Luebkemann C, Schneider G (2020) Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov 19(5):353\u2013364. https:\/\/doi.org\/10.1038\/s41573-019-0050-3","journal-title":"Nat Rev Drug Discov"},{"key":"569_CR28","doi-asserted-by":"publisher","first-page":"107896","DOI":"10.1016\/j.compchemeng.2022.107896","volume":"164","author":"S Nikita","year":"2022","unstructured":"Nikita S, Thakur G, Jesubalan NG, Kulkarni A, Yezhuvath VB, Rathore AS (2022) AI-ML applications in bioprocessing: ML as an enabler of real time quality prediction in continuous manufacturing of mAbs. Comput Chem Eng 164:107896. https:\/\/doi.org\/10.1016\/j.compchemeng.2022.107896","journal-title":"Comput Chem Eng"},{"key":"569_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2031482","author":"R Akbar","year":"2022","unstructured":"Akbar R, Robert PA, Weber CR, Widrich M, Frank R, Pavlovi\u0107 M, Scheffer L, Chernigovskaya M, Snapkov I, Slabodkin A, Mehta BB, Miho E, Lund-Johansen F, Andersen JT, Hochreiter S, Hob\u00e6k Haff I, Klambauer G, Sandve GK, Greiff V (2022) In silico proof of principle of machine learning-based antibody design at unconstrained scale. MAbs. https:\/\/doi.org\/10.1080\/19420862.2022.2031482","journal-title":"MAbs"},{"issue":"8","key":"569_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41592-019-0496-6","volume":"16","author":"KK Yang","year":"2019","unstructured":"Yang KK, Wu Z, Arnold FH (2019) Machine-learning-guided directed evolution for protein engineering. Nat Methods 16(8):687\u2013694. https:\/\/doi.org\/10.1038\/s41592-019-0496-6","journal-title":"Nat Methods"},{"issue":"6","key":"569_CR31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41587-021-01179-w","volume":"40","author":"ML Bileschi","year":"2022","unstructured":"Bileschi ML, Belanger D, Bryant DH, Sanderson T, Carter B, Sculley D, Bateman A, DePristo MA, Colwell LJ (2022) Using deep learning to annotate the protein universe. Nat Biotechnol 40(6):932\u2013937. https:\/\/doi.org\/10.1038\/s41587-021-01179-w","journal-title":"Nat Biotechnol"},{"issue":"2","key":"569_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/bioinformatics\/btab660","volume":"38","author":"C Schneider","year":"2022","unstructured":"Schneider C, Buchanan A, Taddese B, Deane CM (2022) DLAB: deep learning methods for structure-based virtual screening of antibodies. Bioinformatics 38(2):377\u2013383. https:\/\/doi.org\/10.1093\/bioinformatics\/btab660","journal-title":"Bioinformatics"},{"key":"569_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejpb.2019.05.017","volume":"141","author":"L Gentiluomo","year":"2019","unstructured":"Gentiluomo L, Roessner D, Augustijn D, Svilenov H, Kulakova A, Mahapatra S, Winter G, Streicher W, Rinnan \u00c5, Peters GHJ, Harris P, Frie\u00df W (2019) Application of interpretable artificial neural networks to early monoclonal antibodies development. Eur J Pharm Biopharm 141:81\u201389. https:\/\/doi.org\/10.1016\/j.ejpb.2019.05.017","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"569_CR34","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/19420862.2018.1518887","volume":"10","author":"K Sankar","year":"2018","unstructured":"Sankar K, Hoi KH, Yin Y, Ramachandran P, Andersen N, Hilderbrand A, McDonald P, Spiess C, Zhang Q (2018) Prediction of methionine oxidation risk in monoclonal antibodies using a machine learning method. MAbs 10(8):1281\u20131290. https:\/\/doi.org\/10.1080\/19420862.2018.1518887","journal-title":"MAbs"},{"issue":"2","key":"569_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/19420862.2015.1007828","volume":"7","author":"O Obrezanova","year":"2015","unstructured":"Obrezanova O, Arnell A, de La Cuesta RG, Berthelot ME, Gallagher TRA, Zurdo J, Stallwood Y (2015) Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs 7(2):352\u2013363. https:\/\/doi.org\/10.1080\/19420862.2015.1007828","journal-title":"MAbs"},{"issue":"5","key":"569_CR36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, V\u00e1squez M, Wittrup KD (2017) Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci USA 114(5):944\u2013949. https:\/\/doi.org\/10.1073\/pnas.1616408114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"569_CR37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.copbio.2011.06.002","volume":"22","author":"J L\u00f6fblom","year":"2011","unstructured":"L\u00f6fblom J, Frejd FY, St\u00e5hl S (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 22(6):843\u2013848. https:\/\/doi.org\/10.1016\/j.copbio.2011.06.002","journal-title":"Curr Opin Biotechnol"},{"key":"569_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/9783527699124.ch6","author":"NK Mehta","year":"2017","unstructured":"Mehta NK, Cochran JR (2017) Beyond antibodies: engineered protein scaffolds for therapeutic development. Protein Ther. https:\/\/doi.org\/10.1002\/9783527699124.ch6","journal-title":"Protein Ther"},{"key":"569_CR39","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2009) ICH guideline Q8 (R2) on pharmaceutical development"},{"key":"569_CR40","unstructured":"Molecular Operating Environment (MOE), 2022.02 Chemical computing group ULC, 910\u20131010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada. (2022)"},{"issue":"8","key":"569_CR41","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1021\/bi992215v","volume":"39","author":"DH Goetz","year":"2000","unstructured":"Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK (2000) Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39(8):1935\u20131941. https:\/\/doi.org\/10.1021\/bi992215v","journal-title":"Biochemistry"},{"issue":"11","key":"569_CR42","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/bioinformatics\/btv042","volume":"31","author":"N Xiao","year":"2015","unstructured":"Xiao N, Cao D-S, Zhu M-F, Xu Q-S (2015) protr\/ProtrWeb: R package and web server for generating various numerical representation schemes of protein sequences. Bioinformatics 31(11):1857\u20131859. https:\/\/doi.org\/10.1093\/bioinformatics\/btv042","journal-title":"Bioinformatics"},{"key":"569_CR43","doi-asserted-by":"crossref","unstructured":"Xiao N (2015) protr: R package for generating various numerical representation schemes of protein sequences. https:\/\/cran.r-project.org\/web\/packages\/protr\/vignettes\/protr.html","DOI":"10.1093\/bioinformatics\/btv042"},{"issue":"1","key":"569_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ (2011) Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 20(1):40\u201349. https:\/\/doi.org\/10.1002\/mpr.329","journal-title":"Int J Methods Psychiatr Res"},{"key":"569_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1418-1","volume-title":"An introduction to statistical learning with applications in R","author":"G James","year":"2021","unstructured":"James G, Witten D, Hastie T, Tibshirani R (2021) An introduction to statistical learning with applications in R, 2nd edn. Springer, New York","edition":"2"},{"key":"569_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.conengprac.2017.09.018","volume":"70","author":"SN Thennadil","year":"2018","unstructured":"Thennadil SN, Dewar M, Herdsman C, Nordon A, Becker E (2018) Automated weighted outlier detection technique for multivariate data. Control Eng Pract 70:40\u201349. https:\/\/doi.org\/10.1016\/j.conengprac.2017.09.018","journal-title":"Control Eng Pract"},{"key":"569_CR47","unstructured":"R Core Team (2022) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"key":"569_CR48","doi-asserted-by":"publisher","first-page":"103937","DOI":"10.1016\/j.chemolab.2020.103937","volume":"198","author":"S Kucheryavskiy","year":"2020","unstructured":"Kucheryavskiy S (2020) mdatools\u2014R package for chemometrics. Chemom Intell Lab Syst 198:103937. https:\/\/doi.org\/10.1016\/j.chemolab.2020.103937","journal-title":"Chemom Intell Lab Syst"},{"key":"569_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm998","author":"S Kawashima","year":"2007","unstructured":"Kawashima S, Pokarowski P, Pokarowska M, Kolinski A, Katayama T, Kanehisa M (2007) AAindex: amino acid index database, progress report 2008. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkm998","journal-title":"Nucleic Acids Res"},{"key":"569_CR50","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v028.i05","author":"M Kuhn","year":"2008","unstructured":"Kuhn M (2008) Building predictive models in R using the caret package. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v028.i05","journal-title":"J Stat Softw"},{"key":"569_CR51","first-page":"359","volume":"4","author":"G Moreau","year":"1980","unstructured":"Moreau G, Broto P (1980) The autocorrelation of a topological structure: a new molecular descriptor. NouV J Chim 4:359\u2013360","journal-title":"NouV J Chim"},{"key":"569_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2200540","author":"T Jain","year":"2023","unstructured":"Jain T, Boland T, V\u00e1squez M (2023) Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches. MAbs. https:\/\/doi.org\/10.1080\/19420862.2023.2200540","journal-title":"MAbs"},{"key":"569_CR53","unstructured":"Thomas D, Chancellor D, Micklus A, LaFever S, Hay M, Chaudhuri S, Bowden R, W Lo A (2021) Clinical development success rates and contributing factors 2011\u20132020"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-024-00569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-024-00569-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-024-00569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:17:18Z","timestamp":1732605438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-024-00569-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s10822-024-00569-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.10.566515","asserted-by":"object"}]},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests:  J-P. Mayer, R. Kumar, T. Eichner, K. Felderer and H. Kaufmann were employees of Pieris Pharmaceuticals GmbH at the time the work covered in this article was conducted.  Daniel A.M. Pais, Sofia T. Santos, Maria B. Batalha and Sandra D. Silva  are employees of Valgenesis Portugal, Lda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"30"}}